MedTrace Logo

Metformin Plus Irinotecan for Refractory Colorectal Cancer

NCT01930864 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-06-22

No results posted yet for this study

Summary

MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.

Conditions

  • Colorectal Neoplasms
  • Adenocarcinoma

Interventions

DRUG

metformin

metformin up to 2500mg/d

DRUG

irinotecan

Irinotecan 350 mg/m² IV q21d

Sponsors & Collaborators

  • University of Campinas, Brazil

    collaborator OTHER

  • AC Camargo Cancer Center

    collaborator OTHER

  • Barretos Cancer Hospital

    lead OTHER

Principal Investigators

  • Joao Paulo SN Lima, MD, PhD · AC Camargo Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2020-12-01
Completion
2020-12-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01930864 on ClinicalTrials.gov